Chronic Alcoholism Model

Indication / Application

Efficacy validation of therapeutics for Alcoholic Liver Disease (ALD/ASH), screening of neuroprotective agents targeting alcohol-induced brain damage or withdrawal cognitive deficits, evaluation of mucosal protectants restoring gut-barrier integrity, and pharmacological research on alcohol addiction and withdrawal-related behaviors.

Modeling Method

1. Lieber-DeCarli Liquid Diet Feeding (Physiological Ad Libitum Exposure):

• Animals are fed an isomerous liquid diet where dextrin is gradually replaced by ethanol (typically comprising 5% v/v or 36% of total caloric intake) over a 4 to 6-week period. This established method ensures voluntary, continuous, and high-dose ethanol intake without nutritional deficiency or dehydration, mimicking chronic human drinking patterns.

2. Chronic-Plus-Single Binge Protocol (NIAAA Model for Acute-on-Chronic Injury):

• Animals undergo a 10-day ad libitum Lieber-DeCarli liquid diet, followed by a single, controlled gavage of ethanol on Day 11. This dual-hit protocol reliably induces a significant spike in blood alcohol levels, mimicking human acute-on-chronic alcoholic hepatitis, characterized by marked neutrophil infiltration and elevated serum transaminases.

3. Intragastric Intubation Model (Tsukamoto-French Method):

• Continuous infusion of ethanol and specialized diets via an implanted gastric cannula to control precise intake and guarantee severe, progressive steatohepatitis and early bridging fibrosis.

Clinical Relevance

• Multi-Organ Pathological Homology: Our protocols mirror the human clinical progression of alcoholism, demonstrating hepatic micro/macrovesicular steatosis, elevated liver enzymes, neuro-inflammatory microglia activation, and down-regulated tight junction proteins in the distal intestine.

• Translational Inflammatory Profile: The chronic-plus-binge protocol mimics the clinical "flare-up" of alcoholic hepatitis, providing a critical window for testing compounds aimed at dampening inflammatory cytokines and neutrophil recruitment.

Key Evaluation Endpoints

In Vivo, Neurobehavioral & Metabolic Evaluation

• Blood Alcohol Concentration (BAC): Precise gas chromatography or enzymatic assay monitoring of systemic ethanol levels.

• Neurobehavioral Assessment (Withdrawal & Addiction Profiling): Evaluation of locomotor activity (open field test), anxiety-like behaviors (elevated plus maze), and somatic withdrawal signs (tremors, tail stiffness, irritability) post-ethanol deprivation.

• Body Weight & Dietary Intake Kinetics: Daily recording of liquid diet consumption and corresponding animal body mass variations.

Histopathology & Tissue Remodeling (Hepatic, Neural & Gastrointestinal)

• Hepatic Fat Deposition & Inflammation (Gold Standard): H&E staining for ballooning degeneration and lobular inflammation, paired with Oil Red O staining on frozen liver sections to quantify neutral lipid accumulation.

• Intestinal Barrier Breakdown: Histological assessment of the ileum and colon, combined with IHC staining of tight junction proteins (Claudin-1, Occludin, and ZO-1) to evaluate "leaky gut" pathology.

• Neuro-inflammatory Microenvironment: H&E and immunohistochemistry (IHC) profiling of GFAP (astrocytes) and Iba1 (microglia) activation in the hippocampus and prefrontal cortex.

Biochemical & Molecular Biomarkers

• Hepatic Injury Ensembles: Standard serum ALT, AST, ALP, total bilirubin, and triglyceride (TG) quantification.

• Endotoxemia Markers: Quantification of circulating Lipopolysaccharides (LPS) in portal and systemic blood via LAL assays, indicating gut-barrier failure and bacterial translocation.

• Localized Inflammatory Cytokines: Quantitative PCR (RT-qPCR) and multiplex ELISA profiling of tissue-specific pro-inflammatory mediators (TNF-alpha, IL-1beta, IL-6, MCP-1) and oxidative stress markers (MDA, CYP2E1 activity, and GSH levels).